Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic commences enrolment for new ablation study

Medtronic commences enrolment for new ablation study

25th January 2012

Medtronic has commenced enrolment for a new clinical study that will evaluate the efficacy of its Arctic Front Cardiac CryoAblation System.

The first patient has been recruited for the Fire and Ice trial, a multinational head-to-head study that will compare the safety, efficacy and ease of use of Medtronic's product to a radiofrequency ablation solution from Biosense Webster.

Both treatment options are designed to bring benefits to patients with symptomatic paroxysmal atrial fibrillation, a largely underserved group.

The Arctic Front system has already shown various short and long-term benefits in earlier clinical studies, with Medtronic hoping that the latest trial will demonstrate that cryoballoon ablation can offer a viable alternative therapy option among this group.

Reggie Groves, vice-president and general manager of Medtronic's atrial fibrillation solutions business, said: "Medtronic is committed to building upon a strong foundation of scientific evidence to help inform physicians' clinical decisions and help them select technologies that are best suited for their individual patients."

This comes in the same week that Medtronic completed enrolment for the extreme risk patient group in a new study of its product CoreValve.ADNFCR-8000103-ID-801274632-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.